Synthesis, saccharide-binding and anti-cancer cell proliferation properties of arylboronic acid derivatives of indoquinolines

Chemical Biology and Drug Design

Volumn 78, Issue 5, 2011, Pages 816-825

  Meng, Junxiu ^a   Yu, Shaoqing ^a   Wan, Shengbiao ^a   Ren, Sumei ^a   Jiang, Tao ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Anti cancer cell proliferation; Boronic acid; Indoloquinoline; Saccharide

Indexed keywords

10,11 DIHYDRO 11 OXO 5H INDOLO[3,2 B]QUINOLINE 7 CARBOXYLIC ACID; 10,11 DIHYDRO 11 OXO 5H INDOLO[3,2 B]QUINOLINE 9 CARBOXYLIC ACID; 10H INDOLO[3,2 B]QUINOLINE 7 CARBOXYLIC ACID; 11 CHLORO 10H INDOLO[3,2 B]QUINOLINE 7 CARBOXYLIC ACID; 11 CHLORO 10H INDOLO[3,2 B]QUINOLINE 9 CARBOXYLIC ACID; 3 (10H INDOLO[3,2 B]QUINOLINE 7 CARBOXAMIDO)PHENYLBORONIC ACID; 3 (11 CHLORO 10H INDOLO[3,2 B]QUINOLINE 7 CARBOXAMIDO)PHENYLBORONIC ACID; 3 (11 CHLORO 10H INDOLO[3,2 B]QUINOLINE 9 CARBOXAMIDO)PHENYLBORONIC ACID; ANTINEOPLASTIC AGENT; ARYLBORONIC ACID DERIVATIVE; BORONIC ACID DERIVATIVE; FUCOSE; GALACTOSE; GLUCOSE; INDOLOQUINOLINE DERIVATIVE; PACLITAXEL; SIALIC ACID; UNCLASSIFIED DRUG;

AMIDATION; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; AROMATIZATION; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; CYCLIZATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; NEGATIVE ION ELECTROSPRAY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARBOHYDRATES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MASS SPECTROMETRY; NEOPLASMS; QUINOLINES;

EID: 80054114625     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01196.x     Document Type: Article

References (40)

1. Brandley B.K., Schnaar R.L. (1986) Cell-surface carbohydrates in cell recognition and response. J Leukoc Biol;40:97-111.
2. Fischer F., Egg G. (1990) N-acetylneuraminic acid (sialic acid) as a tumor marker in head and neck cancers. HNO;38:361-363.
3. Listinsky J.J., Listinsky C.M., Alapati V., Siegal G.P. (2001) Cell surface fucose ablation as a therapeutic strategy for malignant neoplasms. Adv Anat Pathol;8:330-337.
4. Lorand J.P., Edwards J.O. (1959) Polyol complexes and structure of the benzeneboronate ion. J Org Chem;24:769-774.
5. Norrild J.C., Eggert H. (1995) Evidence for mono- and bisdentate boronate complexes of glucose in the furanose form. Application of 1JC-C coupling constants as a structural probe. J Am Chem Soc;117:1479-1484.
6. Rohovec J., Maschmeyer T., Aime S., Peters J.A. (2003) The structure of the sugar residue in glycated human serum albumin and its molecular recognition by phenylboronate. Chemistry;9:2193-2199.
7. Nagai Y., Kobayashi K., Toi H., Aoyama Y. (1993) Stabilization of sugar-boronic esters of indolylboronic acid in water via sugar-indole interaction: a notable selectivity in oligosaccharides. Bull Chem Soc Jpn;66:2965-2971.
8. Suenaga H., Mikami M., Sandanayake K.R.A.S., Shinkai S. (1995) Screening of fluorescent boronic acids for sugar sensing which show a large fluorescence change. Tetrahedron Lett;36:4825-4828.
9. Arimori S., Bosch L.I., Ward C.J., James T.D. (2001) Fluorescent internal charge transfer (ICT) saccharide sensor. Tetrahedron Lett;42:4553-4555.
10. Suri J.T., Cordes D.B., Cappuccio F.E., Wessling R.A., Singaram B. (2003) Continuous glucose sensing with a fluorescent thin-film hydrogel. Angew Chem;115:6037-6039.
11. Bosch L.I., Mahon M.F., James T.D. (2004) The B-N bond controls the balance between locally excited (LE) and twisted internal charge transfer (TICT) states observed for aniline based fluorescent saccharide sensors. Tetrahedron Lett;45:2859-2862.
12. Zhang Y., Gao X., Hardcastle K., Wang B. (2006) Water-soluble fluorescent boronic acid compounds for saccharide sensing: substituent effects on their fluorescence properties. Chemistry;12:1377-1384.
13. Peter J.D., Daniel A.O. (2009) Remarkably selective saccharide recognition by solid-supported peptide boronic acids. Tetrahedron;65:109-114.
14. Mohler L.K., Czarnik A.W. (1993) Ribonucleoside membrane transport by a new class of synthetic carrier. J Am Chem Soc;115:2998-2999.
15. Mohler L.K., Czarnik A.W. (1993) Alpha-amino acid chelative complexation by an arylboronic acid. J Am Chem Soc;115:7037-7038.
16. Kataoka K., Miyazaki H., Bunya M., Okano T., Sakurai Y. (1998) Totally synthetic polymer gels responding to external glucose concentration: their preparation and application to on-off regulation of insulin release. J Am Chem Soc;120:12694-12695.
17. Yang W., Gao S., Gao X., Karnati V.R., Ni W., Wang B., Hooks W.B., Carson J., Weston B. (2002) Diboronic acids as fluorescent probes for cells expressing sialyl Lewis X. Bioorg Med Chem Lett;12:2175-2177.
18. Yang W., Fan H., Gao X., Gao S., Karnati V., Ni W., Hooks W., Carson J., Weston B., Wang B. (2004) The first fluorescent diboronic acid sensor specific for hepatocellular carcinoma cells expressing sialyl Lewis X. Chem Biol;11:439-448.
19. Dwuma-Badu D., Ayin J.S.K., Fiagbe N.I., Knapp J.E., Schiff P.L.J., Slatkin D.J. (1978) Constituents of west african medicinal plants XX: quindoline from Cryptolepis sanguinolenta. J Pharm Sci;67:433-434.
20. Boye G.L., Ampofo O. (1983) Clinical uses of Cryptolepis sanguinolenta. In: Proceedings of the First International Seminar on Cryptolepine. Kumasi, Ghana: University of Science and Technology; p. 37-40.
21. Paulo A., Gomes E.T., Steele J., Warhurst D.C., Houghton P.J. (2000) Antiplasmodial activity of Cryptolepis sanguinolenta alkaloids from leaves and roots. Planta Med;66:30-34.
22. Oliver-Bever B.E.P. (1986) Medicinal Plants in Tropical West Africa. Cambridge, London: Cambridge University Press.
23. Bamgbose S.O., Noamesi B.K. (1981) Studies on cryptolepine II: inhibition of carragenan induced oedema by cryptolepine. Planta Med;41:392-396.
24. Olajide O.A., Ajayi A.M., Wright C.W. (2009) Anti-inflammatory properties of cryptolepine. Phytother Res;23:1421-1425.
25. Dassonneville L., Lansiaux A., Wattelet A., Wattez N., Mahieu C., Van-Miert S., Pieters L., Bailly C. (2000) Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Eur J Pharmacol;409:9-18.
26. Bonjean K., De Pauw-Gillet M.C., Defresne M.P., Colson P., Houssier C., Dassonneville L., Bailly C., Wright C., Quetin-Leclercq J., Angenot L. (1997) Cryptolepine is a potent DNA intercalating agent which inhibits selectively DNA synthesis in B16 melanoma cells cultured in vitro. Anticancer Res;17:4068-4069.
27. Lisgarten J.N., Coll M., Portugal J., Wright C.W., Aymami J. (2002) The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat Struct Biol;9:57-60.
28. Guittat L., Alberti P., Rosu F., Van Miert S., Thetiot E., Pieters L., Gabelica V., De Pauw E., Ottaviani A., Riou J.F., Mergny J.L. (2003) Interactions of cryptolepine and neocryptolepine with unusual DNA structures. Biochimie;85:535-547.
29. Bonjean K., De Pauw-Gillet M.C., Defresne M.P., Colson P., Houssier C., Dassonneville L., Bailly C., Greimers R., Wright C., Quetin-Leclercq J., Tits M., Angenot L. (1998) The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry;37:5136-5146.
30. Bailly C., Laine W., Baldeyrou B., De P.G., Colson P., Houssier C., Cimanga K., Van Miert S., Vlietinck A.J., Pieters L. (2000) DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepine. Anticancer Drug Des;10:191-201.
31. Guyen B., Schultes C.M., Hazel P., Mann J., Neidle S. (2004) Synthesis and evaluation of analogues of 10H-indolo[3, 2-b]quinoline as G-quadruplex stabilising ligands and potential inhibitors of The enzyme telomerase. Org Biomol Chem;2:981-988.
32. Caprio V., Guyen B., Opoku-Boahen Y., Mann J., Gowa S.M., Kellan L.M., Read M.A., Neidle S. (2000) A novel inhibitor of human telomerase derived from 10H-indolo[3, 2-b]quinoline. Bioorg Med Chem Lett;10:2063-2066.
33. Zhou J.L., Lu Y.J., Ou T.M., Zhou J.M., Huang Z.S., Zhu X.F., Du C.J., Bu X.Z., Ma L., Gu L.Q., Li Y.M., Chan A.S.C. (2005) Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase. J Med Chem;48:7315-7321.
34. Sunder S., Peet N.P. (1978) Syntheis of benzofuro[3, 2-b]quinolin-6(11H)one and derivatives. J heterocycl Chem;15:1379-1382.
35. Yamato M., Takeuchi Y., Chang M.R., Hashigaki K., Tsuruo T., Tashiro T., Tsukagoshi S. (1990) Synthesis and antitumor activity of fused quinoline derivatives. Chem Pharm Bull;38:3048-3052.
36. Takeuchi Y., Chang M.R., Hashigaki K., Yamato M. (1991) Synthesis and antitumor activity of 7-(N-glycosylamino)-indolo[3, 2-b]quinolines. Chem Pharm Bull;39:1629-1631.
37. Ormerod D., Willemsens B., Mermans R., Langens J., Winderickx G., Kalindjian S.B., Buck I.M., Mcdonald I.M. (2005) Development of a scalable synthesis of gastrazole (JB95008): a potent CCK2 receptor antagonist. Org Process Res Dev;9:499-507.
38. Anthony P.N., Neville J.H., David E.G. (1993) An investigation into the stereochemistry of the boronate di-esters of some monosaccharides using tandem mass spectrometry. Rapid Commun Mass Spectrom;7:1099-1107.
39. Giusti M.M., Rodri'guez-Saona L.E., Griffin D., Wrolstad R.E. (1999) Electrospray and tandem mass spectroscopy as tools for anthocyanin characterization. J Agric Food Chem;47:4657-4664.
40. Chai Q., Piskarev V., Lawson A.M. (2001) Negative-ion electrospray mass spectrometry of neutral underivatized oligosaccharides. Anal Chem;73:651-657.